



Vitamin D3 Treatment Decreases Frequencies of CD16-Positive and TNF- α -Secreting Monocytes in Asthmatic Patients

Grubczak K, Lipinska D, Eljaszewicz A, Singh P, Radzikowska U, Miklasz P, Dabrowska M, Jablonska E, Bodzenta-Lukaszyk A, Moniuszko M

Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok

Description

Previously, we demonstrated that glucocorticoid (GC) treatment of asthmatic patients resulted in decreasing frequencies of monocyte subsets expressing CD16 and capable of releasing TNF- α . Here, we wished to analyze whether active form of vitamin D (vitamin D₃, 1,25-(OH)₂D₃) can exert GC-like proapoptotic effects on CD16-positive monocytes and thus decrease proinflammatory potential of these cells. Finally, we set out to investigate whether the addition of 1,25-(OH)₂D₃ would facilitate use of lower GC doses without decreasing their antiinflammatory properties.

Peripheral blood mononuclear cells collected from healthy individuals and asthmatic patients were cultured with 1,25-(OH)₂D₃ and/or varying doses of GC in presence or absence of caspase inhibition. Cells were either directly stained for extracellular markers or prestimulated with lipopolysaccharide for assessment of intracellular cytokine production and then analyzed by flow cytometry.

We found that 1,25-(OH)₂D₃ alone (and in combination with GC) decreased frequency of CD14⁺⁺CD16⁺ and CD14⁺CD16⁺⁺ monocytes from asthmatic patients and significantly diminished TNF- α production by monocytes. With regard to the CD14⁺CD16⁺⁺ subset, monocyte-depleting effects of 1,25-(OH)₂D₃ were abrogated in the presence of pan-caspase inhibitor, suggesting proapoptotic mechanism of 1,25-(OH)₂D₃ action. Interestingly, we found that combined treatment of 1,25-(OH)₂D₃ and GC allowed for 5-fold reduction of the GC dose while maintaining their anti-inflammatory effects.

This study has revealed novel immunomodulatory properties of 1,25-(OH)₂D₃ directed against monocyte subsets capable of TNF- α production. In addition, our data suggest that introduction of 1,25-(OH)₂D₃ to antiinflammatory therapy would possibly allow for use of lower GC doses.